Research Roundup: Engineered Nanoparticles and New Potential Standards of Care
Positive results from a phase 3 trial of Astellas Pharmaceuticals’ zolbetuximab and modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) “may represent a... Read More
